24 April 2026
In plain English
Eli Lilly's weight-loss pill Foundayo — the first oral competitor to Novo Nordisk's Wegovy pill — has been shipping from US pharmacies since April 6. Both are priced at $149 a month without insurance.
Legal analysts are now flagging that the FDA's recent removal of 12 experimental drugs called peptides (short protein fragments used for recovery and longevity) from its restricted list does not actually authorize specialty pharmacies to make them. The July 23 advisory meeting remains the gate.
In pet health, a company called Loyal just cleared two of three major FDA hurdles for a daily pill designed to extend dogs' lifespans — the first drug of its kind, possibly on the market by year's end. Two other companies are testing weight-loss drugs for overweight cats. Quiet day otherwise.
Signal detail
· delta −0.02 Resolving the April 22 adjudication. The 10:52 UTC run that day captured a signal the 15:30 run did not: the FDA explicitly stated there has been no spike in adverse events from compounded peptides. This is the strongest negative signal against a headline-grade incident and warrants acknowledgment. The Cat 1 reclassification track also introduces a paradox — channeling demand from gray-market to regulated specialty compounding pharmacies could reduce contamination rates even as adoption volumes rise. Modest downward revision reflects both signals.
Adoption velocity is the denominator. Even if contamination rates fall, absolute adverse events rise with volume. ProPublica, WaPo, and NPR already have investigative templates ready.
New signal: health insurers are publicly balking at Medicare coverage for obesity drugs, with LLY and NVO stocks sliding on the news. Part D plan sponsors have no financial stake in the Bridge (costs borne by CMS central processor) and no marketing incentive to promote it. This adds friction on top of the already complex enrollment mechanism — prior authorization, BMI verification, physician re-prescribing. Foundayo's addition as a third eligible medication modestly broadens formulary options but does not change the structural friction. Extension to December 2027 continues to signal CMS's own expectation of slow ramp.
$50 copay for a $1,000+ drug overwhelms all friction for motivated beneficiaries with comorbidities.
Resolutions & upcoming
No overdue forecasts. No forecasts resolved since last run.
Upcoming resolution dates: - bpc157-pcac-2026 and pcac-july-multi-peptide: July 23, 2026 (90 days) - compound-peptide-property-live: July 31, 2026 (98 days) - medicare-glp1-bridge-uptake, peptide-affiliate-share, hims-peptide-launch: December 31, 2026 - peptide-safety-incident: March 31, 2027
How Barque got smarter today
- Adjudication resolved. The persistent April 22 split (peptide-safety-incident 0.62 vs 0.65) is settled at 0.63. Protocol note: when two same-day runs diverge, the one with the stronger cited evidence should anchor the next run's prior.
- Ring 1 coverage gaps identified. Pet health and menopause/HRT are Ring 1 domains with zero active forecasts. Loyal LOY-002 provides the first strong pet health forecast candidate. Menopause remains unforecast — BioPharma Dive's "revolution hasn't arrived" piece reports a $17B market with structural barriers but no clear falsifiable prediction emerged today.
- Skincare domain unsampled. No signals pulled for skincare (topical peptides) this run. Flagged for next session.
- Sources sampled. Tier 1: FDA bulk substances list, FDA advisory calendar, CNBC, FiercePharma, BioPharma Dive, AJMC, CMS.gov, DVM360, Fortune, Newsweek. Tier 2: Reddit r/peptides (fetch blocked), pet health trade. Tier 3: none.
- WebFetch reliability degraded. All WebFetch attempts returned 403 errors. Signal depth per source relies on search snippets only. If this persists, consider alternative fetch infrastructure.